Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.72
+1.08 (3.91%)
At close: Mar 27, 2026
Market Cap3.91B
Revenue (ttm)2.34M -13.4%
Net Income-123.26M
EPS-11.28
Shares Out136.22M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume131,100
Average Volume188,445
Open27.34
Previous Close27.64
Day's Range26.76 - 29.00
52-Week Range13.48 - 32.00
Beta0.84
RSI78.67
Earnings DateMar 27, 2026

About HKG:3378

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases. The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways. The company was incorporated in 2014 and is headquartered in Wuhan, China. [Read more]

Founded 2014
Employees 55
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3378
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements